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Background/aim: We aimed to present the clinical results of patients with medullary carcinoma under follow-up in our center and to
determine parameters affecting remission and lymph node metastases.
Material and methods: A retrospective analysis was performed of the medical records of 27 patients with MTC who were followed up
between 2004 and 2020.
Results: The mean age at diagnosis was 47.7 ± 14 years. The mean follow-up was 7.29 ± 4.9 years. Metastatic neck lymphadenopathy
was detected in eight (29.6%) patients; none had distant metastasis at the time of diagnosis. The median tumor diameter was 1.50 (range:
0.4–6) cm. The median postoperative calcitonin level was 3.3 (range, 0.5–871) ng/L. Relapse occurred in 2 (range, 1–14) years after
the first surgery in three (11.1%) patients. In the last visit, 7 (25.9%) patients had a structural incomplete response, and three (11.1%)
patients had a biochemical incomplete response. Seventeen (59.3%) patients were in remission, no patients died of MTC or any other
cause. Elevated postoperative calcitonin level was a significant prognostic parameter for remission (p = 0.12) and lymph node metastasis
(p < 0.001).
Conclusion: Elevated postoperative calcitonin level and perithyroid soft tissue invasion were significant prognostic parameters for
remission and lymph node metastasis. Postoperative calcitonin level and calcitonin doubling time should be considered for prognostic
and survival risk assessments.
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1. Introduction
Thyroid cancers constitute 2%–3% of all malignancies.
Although medullary thyroid cancer (MTC) represents 2%–
4% of thyroid cancers, it is associated with higher mortality
compared with differentiated thyroid carcinomas [1]. MTC
is mostly sporadic (70%–95%), approximately 25% are a
part of familial forms, such as multiple endocrine neoplasm
2 (MEN). The major presentation is a thyroid nodule in
70% of sporadic cases [1,2].
Surgery is the only successful option for the treatment
of MTC. The extent of surgery and early excision is pivotal
[1]. Radiotherapy has limited efficacy in medullary thyroid
cancer, and radiotherapy is recommended to be given only
in patients with a high risk of local relapse in those who have
a positive surgical margin or invasion to adjacent tissues
[3]. Patients with progressive metastatic disease who cannot
be treated by surgery or radiotherapy should be considered
candidates for systemic therapy, which includes the usage of
tyrosine kinase inhibitors that target VEGFR and RET [4].
Serum calcitonin and CEA levels are substantial in
determining remission. Persistent high calcitonin levels

after surgery, which is observed in more than half of all
patients, indicate metastatic or residual disease [5,6].
Herein, we aimed to present the data of patients with
MTC under follow-up in our center and to define factors
that affected remission.
2. Materials and methods
2.1. Patients’ clinical and laboratory evaluation
This study included 27 patients with MTC who were
followed up at Marmara University School of Medicine,
Endocrinology and Metabolism outpatient clinic between
2004 to 2020. The patients’ clinical characteristics,
laboratory-imaging findings, and medical histories were
obtained retrospectively from medical charts and the
automation system. The study protocol was approved by
the local ethics committee of Marmara University School
of Medicine (09.2020.683).
Serum calcitonin and carcinoembryonic antigen
(CEA) levels were determined in all patients using
an electrochemiluminescence immunoassay method
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(Axsym, Abbott Laboratories, Tokyo, Japan). The normal
reference range was < 5 pg/mL for calcitonin, and < 2.5 ng/
mL for CEA.
2.2. Endocrinologic evaluation
The parameters of disease activity were evaluated at least
3 months after the surgery. Patients were evaluated for
remission every 3 months for the first year after surgery
and, thereafter, once every six months. Remission was
defined in the case of an undetectable calcitonin level
and normal-range CEA in the absence of structurally
identifiable disease. Biochemical incomplete response was
determined in patients with detectable calcitonin levels or
elevated CEA in the absence of a structurally identifiable
disease. Structural incomplete response was defined as the
presence of recurrent or persistent structurally identifiable
disease [7]. In case of high postoperative calcitonin
levels, staging workup was done to exclude metastases
with computerized tomography (CT) scans and liver
magnetic resonance imaging (MRI), and FDG-PET CT
was performed in suspicious subjects.
2.3. Statistical analyses
The distribution of the data was examined using the
Shapiro–Wilk test. Comparisons between two independent
groups were compared using the Mann–Whitney U test.
Comparisons between categorical variables were made
using Pearson’s Chi-square test, Fisher’s exact test, and
the Fisher–Freeman–Halton test. Descriptive statistics of
the data are given as median (min-max) and n (%). All
statistical analyses were performed and reported using the
IBM SPSS Statistics 20.0 program (IBM Corp., Armonk,
NY, USA). The results were evaluated at a 95% confidence
interval, and p < 0.05 was considered statistically
significant.
3. Results
3.1. Clinical characteristics of patients
The mean age at diagnosis was 47.7 ± 14 years. The female/
male ratio was 2.8. The mean follow-up was 7.29 ± 4.90
years. In 16 patients (59.2%), suspicious ultrasonographic
findings were found, and microcalcifications in the
nodule was detected in 11 patients (40.7%). In 16 (59.2%)
patients, the diagnosis of malignancy was made through
fine-needle aspiration biopsy (FNAB), the remaining
patients were diagnosed after thyroidectomy. In one
patient, the diagnosis was made via biopsy from the
supraclavicular lymph node; there was no nodule on the
thyroid. FNAB was resulted in medullary carcinoma in 10
cases, suspicious for malignancy in 4 cases, and suspicious
for hurthle cell carcinoma in 2 cases. Only 10 cases were
diagnosed correctly by FNAB, but preoperative calcitonin
levels were present in 4 of these suspicious cases, which
were 50 ng/mL,161 ng/mL, 434 ng/mL, and 743 ng/mL,

respectively. No patients had distant metastasis at the time
of diagnosis. RET mutation was evaluated in 16 patients,
and it was heterozygous positive in two (12.5%) patients.
In one of these two patients, bilateral pheochromocytoma
was detected 14 years after the first diagnosis. The patients’
clinical characteristics, pre-postoperative biochemical
results, microscopic features in pathology reports, and
immunohistochemical staining patterns are summarized
in Table 1. Presurgical calcitonin and CEA levels were
present for 16 patients, the median levels were 363.50
pg/mL (min-max: 5–5655) for calcitonin, and 70 ng/mL
(min-max: 9.24–143) for CEA. While thirteen patients
had a baseline calcitonin level higher than 100 pg/mL, it
was above 500 pg/mL in 5 patients. Preoperative lymph
node metastasis was present in 2 of these 5 patients.
Papillary thyroid microcarcinoma was detected in
the contralateral thyroid lobe in three (11.1%) patients.
Postoperative residue was detected in six (22.2%) patients.
Relapse occurred in a median of 2 (range, 1–14) years
after the first surgery in three (11.1%) patients. Neck
radiotherapy was performed on four (14.8%) patients
with locoregional active disease who had extrathyroidal
extension and nodal invasion. In the last visit, seven (25.9%)
patients had structural incomplete response, and three
(11.1%) patients had biochemical incomplete response.
The remaining 17 (59.3%) patients were in remission. In
the last visit, 1 of the 5 patients with calcitonin levels over
500 pg/mL was in biochemical incomplete response, two
were in structural incomplete response, and the remaining
two patients were in remission. None of the patients died
of MTC or any other cause.
3.2. Factors affecting remission
The clinical, laboratory, and pathologic parameters
according to the presence of remission are shown in Table
2. Postoperative calcitonin level (p = 0.120), minimal
extrathyroid invasion (p = 0.047), and intrathyroidal
extension (without extrathyroidal extension) (p = 0.009)
were significantly associated with remission. Age, sex,
preoperative calcitonin and CEA levels, tumor size, vascular
or lymphatic invasion, pathologic staining patterns, stage,
and lymph node status were not associated with remission
(p > 0.05 for all). The median calcitonin doubling time was
4 yrs (min-max: 1–15) in patients without remission. None
of the clinical and laboratory parameters were associated
with the remission (p > 0.05 for all).
3.3. Factors affecting lymph node metastasis
The clinical and pathologic parameters according to the
lymph node metastasis are shown in Table 3. Postoperative
calcitonin level (p < 0.001), lymphatic invasion (p < 0.001),
minimal extrathyroid invasion (p = 0.014), and surgical
margin positivity (p = 0.045) were associated with lymph
node metastasis (Table 3). Age at the time of the diagnosis,
sex, preoperative calcitonin level, tumor size, vascular or
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Table 1. Clinical characteristics, pre-postoperative biochemical results, microscopic features, and
immunohistochemical staining patterns of pathology results.
Variable
Sex
Thyroid function tests

n (%), median (min-max)
Female
Male
Euthyroid
Hyperthyroid
Hypothyroid

Preoperative calcitonin level, pg/mL
Preoperative CEA, ng/mL
Lymph node metastasis at the time of diagnosis
Tumor localization

Positive
Negative
Right lobe
Left lobe
Bilateral

Total thyroidectomy
Total thyroidectomy+ ipsilateral lymph node dissection
Total thyroidectomy+ contralateral lymph node dissection
Postoperative calcitonin level, pg/mL
Postoperative CEA, ng/mL
Tumor size, cm
Lymphatic invasion
Vascular invasion
Perineural invasion
Tumor capsule invasion
Thyroid capsule invasion
Intrathyroidal extension
Perithyroidal soft tissue invasion
Surgical margin positivity
Calcitonin-IHC
CEA-IHC
Chromogranin A-IHC
Synaptophysin-IHC
Amyloid A -IHC
Congo Red-IHC
Crystal Violet -IHC
HMBE-1 IHC
CK-19 IHC
Galectin 3 IHC
ki-67
Positive lymph node
Positive lymph node maximum diameter, cm
TNM Stage

1
2
3
4

20 (74.1%)
7 (25.9%)
23 (81.5%)
3 (11.1%)
1 (3.7%)
363.50 (5–5655)
70 (9.24–143)
8 (29.6%)
19 (70.4%)
12 (44.4%)
13 (48.1%)
2 (7.4%)
15 (55.6%)
8 (29.6%)
4 (14.8%)
3.30 (0.50–821)
4.49 (0.45–14.60)
1.5 (0.4–6)
6 (22.2%)
10 (37%)
2 (7.4%)
9 (33.3%)
7 (25.9%)
12 (44.4%)
5 (18.5%)
6 (22.2%)
25/25 (100%)
23/23 (100%)
21/21 (100%)
20/20 (100%)
10/18 (55.6%)
8/13 (61.5%)
3/7 (42.8%)
3/7 (42.8%)
6/7 (85.7%)
3/7 (42.8%)
2 (1-5)
5.05 ± 8.46
2.1 (1.5-4)
13 (48.1%)
6 (22.2%)
1 (3.7%)
7 (25.9%)

Sixteen patients had presurgical calcitonin and CEA levels.
IHC, immunohistochemistry (the ratio was given as positive cases/ tested patients); CEA, carcinoembryonic
antigen.
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Table 2. Clinical, laboratory, and pathologic parameters according to remission.
Remission positive
n = 15

Remission negative
n = 12

p

50.33 ± 15.71

42.44 ± 8.50

0.174

Female

11 (55%)

9 (45%)

Male

4 (57.1%)

3 (42.9%)

1.40 (0.40–6)

1.50 (1–3.6)

FNAB

10 (62.5%)

6 (37.5%)

TT

5 (45.5%)

6 (54.5%)

Age
Sex
Tumor size
Diagnostic method
Preoperative calcitonin level, pg/mL

0.999
0.508
0.452

743 (5–5655)

294 (161–434)

Positive

2 (25%)

6 (75%)

Negative

13 (68.4%)

6 (31.6%)

TT

7 (53.8%)

6 (46.2%)

TT+IPSLND

5 (55.6%)

4 (44.4%)

TT+CLND

3 (60%)

2 (40%)

Postoperative calcitonin level, pg/mL

2 (0.50–87.30)

59.24(0.50–821)

0.012

Postoperative CEA, ng/mL

4.60 (0.45–9.08)

3.11(1.49–14.60)

0.961

Lymphatic invasion

2 (33.3%)

4 (66.7%)

0.121

Vascular invasion

5 (50%)

5 (50%)

0.473

Perineural invasion

0 (0.0%)

2 (100%)

0.111

Tumor capsule

6 (54.5%)

5 (45.5%)

0.680

Tumor capsule invasion

5 (55.6%)

4 (44.4%)

0.999

Perithyroidal soft tissue invasion

1 (20%)

4 (80%)

0.047

Intrathyroidal extension

4 (33.3%)

8 (66.7%)

0.009

Surgical margin positivity

2 (33.3%)

4 (66.7%)

0.162

ki-67

2.25 ± 1.89

2.22 ± 1.52

0.953
0.139

Lymph node metastasis at the time of diagnosis

Surgery type

Number of positive lymph node

TNM Stage

0 (0–23)

5 (0–26)

1

9 (69.2%)

4 (30.8%)

2

4 (66.7%)

2 (33.3%)

3

1 (100%)

0 (0.0%)

4

1 (14.3%)

6 (85.7%)

0.438
0.087

0.999

0.066

FNAB, fine-needle aspiration biopsy; TT, total thyroidectomy; IPSLND, ipsilateral lymph node dissection; CLND, contralateral lymph
node dissection

perineural or capsular invasion, and pathologic staining
patterns were not associated with nodal involvement (p >
0.05 for all).
4. Discussion
In this retrospective study, female dominancy was seen,
and 87.5% of patients had sporadic MTC. Locoregional
lymph node metastases were observed in eight patients
(29.6%), and none of the patients had distant metastasis
at the time of diagnosis. Relapse occurred in three
patients (11.1%). Increased postoperative calcitonin
levels and minimal extrathyroid invasion were significant

predictor parameters for remission and lymph node
metastasis. In patients with intrathyroidal extension with
no extrathyroidal extension, remission was lower. On the
other hand, lymph node involvement was more common
in patients with positive surgical margin. In the last visit,
17 (59.3%) patients were in remission, and no patients
died of MTC.
Our metastatic lymph node ratio was lower compared
with previous studies. It was reported that lymph node
involvement could be seen in 50%–75% of patients
with palpable thyroid nodule at the time of diagnosis
[1,8,9]. We can attribute this to the low palpable nodule
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Table 3. Clinical, laboratory, pathological parameters according to lymph node metastasis.
Metastatic lymph node

Positive
n=8

Negative
n = 19

p

Age at the diagnosis

43.25 ± 12.54

49.58 ± 14.56

0.295

Female

8 (100%)

0 (0.0%)

Male

12 (63.2%)

7 (38.8%)

1.55 (0.8-2.5)

1.50 (0.4–6)

FNAB

5 (31.3%)

11 (68.8%)

After TT

3 (27.3%)

8 (72.7%)

Gender
Tumor size
Diagnostic method
Preoperative calcitonin level, pg/mL

0.068
0.834
0.824

433 (161–5169)

294 (5-5655)

TT

2 (15.4%)

11 (84.6%)

TT+IPSLND

4 (44.4%)

5 (55.6%)

TT+CLND

2 (40%)

3 (60%)

Postoperative calcitonin level, pg/mL

98.65 (2.28–821)

2 (0.50–68.49)

<0.001

Postoperative CEA, ng/mL

7.11 ± 5.07

3.43 ± 2.27

0.051

Positive

6 (100%)

0 (0.0%)

Negative

0 (0.0%)

15 (100%)

Positive

5 (50%)

5 (50%)

Negative

2 (16.7%)

10 (83.3%)

Positive

2 (%100)

0 (0.0%)

Negative

4 (22.2%)

14 (77.8%)

Positive

3 (27.3%)

8 (72.7%)

Negative

4 (33.3%)

8 (66.7%)

Positive

3 (33.3%)

6 (66.7%)

Negative

4 (28.6%)

10 (71.4%)

Positive

4 (80%)

1 (20%)

Negative

3 (15.8%)

16 (84.2%)

Positive

6 (50%)

6 (50%)

Negative

1 (8.3%)

11 (91.7%)

Positive

4 (66.7%)

2 (33.3%)

Negative

3 (17.6%)

14 (82.4%)

2.50 ± 2.12

2.20 ± 1.64

Surgery type

Lymphatic invasion
Vascular invasion
Perineural invasion
Tumor capsule
Tumor capsule invasion
Perithyroid soft tissue invasion
Intrathyroid extension
Surgical margin positivity
ki-67

0.797
0.308

<0.001
0.225
0.079
0.999
0.809
0.014
0.069
0.045
0.846

FNAB, fine-needle aspiration biopsy; TT, total thyroidectomy; IPSLND, ipsilateral lymph node dissection; CLND, contralateral lymph
node dissection

(n = 8, 29.6%) rate initially. Medullary thyroid cancer
is frequently metastasized to the central compartment,
followed by levels II through V. Rarely, upper mediastinal
and supraclavicular lymph node involvement can be seen
[10]. Skip metastases are reported in 1.6% to 21.8% of cases
[10]. In our study, one (3.7%) patient had skip metastasis.
Bae et al. reported that basal serum calcitonin levels
and tumor size were associated with lymph node metastasis
[11]. In our study, basal calcitonin levels and tumor size
were not different in patients with or without lymph node
metastasis.

2054

The American Thyroid Association (ATA) guidelines
recommend making the decision for neck dissection
according to calcitonin levels. In patients whose
preoperative calcitonin level is above 20 pg/mL, ipsilateral
central and ipsilateral lateral neck compartment dissection
is recommended. If the calcitonin level is above 200 pg/
mL, even with any ultrasound findings, prophylactic
contralateral lymph node dissection is suggested [1,12]. We
performed prophylactic central lymph node dissection in
accordance with the ATA guidelines in 14 patients, which
were suspicious for medullary thyroid cancer preoperatively.
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Calcitonin levels also correlate with tumor size at the
time of diagnosis [13] and are used as a marker for the
detection of persistent locoregional disease and distant
metastasis in the postoperative period [14]. Calcitonin
levels were correlated with stage in Ismailov et al.’s study
[14], but we found no correlation (p = 0.494). In the
literature, the postoperative calcitonin level was stated as
an important factor for determining survival and prognosis
[1,2,7,15]. Similar to previous studies, the postoperative
calcitonin level was found as a significant predictor of
remission and lymph node metastasis in our study.
In a study conducted by Modigliani et al., 10-year
survival was 97.7% in patients who were biochemically
cured [16]. In patients with high postoperative calcitonin
levels, the 10-year survival was decreased to 70% [16]. In
Clark et al.’s study, the 5-, 10-, and 20-year survival rates
were 97%, 88%, and 84%, respectively. Postoperative
calcitonin levels, vascular invasion, and extrathyroidal
extension were found as factors that affected both diseasefree survival and locoregional control [15]. Barbet et al.
reported that 8% of patients with a calcitonin doubling
time shorter than 6 months had 10-year survival, and
no patients died of MTC in the 10-year follow-up period
whose doubling time was more than 24 months [17]. They
also stated that the calcitonin doubling time might be
superior to staging, and that it was the strongest prognostic
factor [17,18]. In our study, the whole patients’ calcitonin
doubling time was above 2 years, except one patient, which
may explain why there were no deaths.
The limitation of our study is its retrospective design.
To detect prognostic factors, survival rates, and for making
precise interpretations, larger studies with longer followup periods are needed. However, this is difficult to achieve
due to the rarity of MTC.

In conclusion, serum calcitonin is an effective
marker for preoperative diagnosis, evaluating
postoperative remission status, and estimating both
survival and prognosis. Although MTC is known to
have a poor prognosis compared with differentiated
thyroid carcinomas, survival has improved due to early
diagnosis, and to a large extent on surgery based on
preoperative calcitonin levels. Postoperative calcitonin
levels and calcitonin doubling times should be taken
into consideration for the prognostic and survival risk
assessments.
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